Shanghai Henlius Biotech, Inc. (HKG:2696)

Hong Kong · Delayed Price · Currency is HKD

77.55

-2.35 (-2.94%)

Apr 28, 2026, 4:08 PM HKT

104.89% (1Y)

Market Cap	42.15B
Revenue (ttm)	7.42B
Net Income (ttm)	920.34M
Shares Out	543.49M
EPS (ttm)	1.68
PE Ratio	46.15
Forward PE	29.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	307,705
Average Volume	1,339,262
Open	79.90
Previous Close	79.90
Day's Range	77.40 - 80.90
52-Week Range	32.75 - 92.00
Beta	0.51
RSI	50.80
Earnings Date	May 26, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 3,762

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2696

Full Company Profile

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY Financial Statements

News

Shanghai Henlius Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

The session detailed a robust global clinical pipeline, with multiple late-stage assets showing strong efficacy and safety, and several regulatory filings and data readouts expected in 2024. Strategic focus includes next-gen IO, ADCs, and global expansion, with funding from biosimilar sales and partnerships.

3 months ago - Transcripts